Tony Berberabe, MPH

Articles

Molecular Subtypes Prognostic for OS, DFS in Clear-Cell RCC

November 18th 2017

Four molecular subtypes of clear-cell renal cell carcinoma were prognostic for outcomes after metastasectomy, with striking differences seen in overall survival and disease-free survival between each of the groups.

Immunotherapy Overtakes Targeted Therapy as First-Line Standard of Care for mRCC

November 18th 2017

An extension in overall survival seen with the combination of nivolumab and ipilimumab has completely changed the standard of care for patients with metastatic renal cell carcinoma.

Refining Role of Brentuximab Vedotin and Immunotherapy in Hodgkin Lymphoma

November 9th 2017

As clinicians’ understanding of the disease pathobiology associated with Hodgkin lymphoma (HL) has increased, novel treatments have emerged.

Innovators Lauded With Giants Awards

June 2nd 2017

Twelve creative and influential oncology research leaders are the winners of the 2017 Giants of Cancer Care® awards, a unique honor that recognizes physician-scientists who have helped move cancer care forward.

The Latest Luminaries: Meet the 2016 Giants

November 10th 2016

Ten prominent oncology researchers and clinicians have been chosen as the 2016 Giants of Cancer Care® award winners from the largest field of nominees in the 4-year history of the unique OncLive recognition program. The winners were chosen by a panel of esteemed oncology leaders.

Intensified Radiotherapy Emerging as New Standard

October 26th 2016

Radiation therapy can be effectively delivered in more focused, intensive, and shorter-course treatment regimens that offer patients at least equivalent—and in some cases superior—outcomes in several tumor types, thus helping to mitigate challenging adverse effects of standard approaches.

Concurrent Chemoradiation, Radical Cystectomy Demonstrate Similar Median OS Rates in Urothelial Cancer

October 14th 2016

In a propensity-matched analysis of a national cancer registry, patients who underwent radical cystectomy or concurrent chemoradiation to treat urothelial cancer demonstrated statistically similar median overall survival rates. Further analysis suggests that the hazard ratios between the two treatments change over time and is hypothesis generating.

Computer Simulation Helps Plan Transducer Placement in Glioblastoma

October 13th 2016

For patients who are likely to experience contiguous recurrence of glioblastoma, a new computer simulation using tumor treating fields and employing a personalized transducer array, delivered electric field intensities that exceeded therapeutic intensities in 3 different tumor locations. The findings may aid treatment planning when using the NovoTAL System, which optimizes therapeutic delivery in 2 orthogonal directions to the gross tumor volume and proximal peri-tumoral brain zone.

Minimal Toxicities Reported in Extreme Hypofractionated Comparison Trial in Prostate Cancer

October 10th 2016

Men with intermediate prostate cancer who received extreme hypofractionated radiotherapy reported a low incidence of side effects, with no significant differences compared with a similar cohort of men who received conventional fractionation after 2 years of treatment.

H-RT Reduces Treatment Time by One-Third in Low-Risk Prostate Cancer

October 5th 2016

Study results that examined patient-reported outcomes and quality of life measures demonstrate that hypofractionated radiotherapy is a viable, safe, and value-added alternative to patients with low-risk prostate cancer.

Similar Survival Rates Reported Across Treatment Options for Localized Prostate Cancer

September 21st 2016

Treatment options for men with localized prostate cancer include active surveillance, radical prostatectomy, or external-beam radiotherapy, but in the Prostate Testing for Cancer and Treatment trial each therapy was associated with a low prostate-specific mortality rate of about 1%.

QOL in Men Undergoing Monitoring for Prostate Cancer Similar to Men With No Disease

September 19th 2016

Men with positive needle biopsy for prostate cancer who underwent active surveillance exhibited no difference in quality-of-life compared with men who had a negative prostate needle biopsy.

Rio Grande Urology Expands With Gynecologic Oncology Collaboration

August 14th 2016

As a group, Rio Grande Urology shares a sense of obligation and culture. Its leaders have embraced an integrative model approach and sees the advantages of it.

Survival Improved With Surgery/Targeted Therapy Combo in Renal Cell Carcinoma

August 13th 2016

Patients with renal cancer who underwent cytoreductive nephrectomy and targeted therapy had improved survival compared with patients who did not undergo the surgery.

Signature Trial Program Aims for Rapid Delivery of Novel Therapies

August 4th 2016

A collection of clinical trials that uses a target-specific and tissue-agnostic algorithm to rapidly match patients to investigational therapies aimed at the tumor's molecular makeup takes the approach that "one trial really does not fit all."

With Its Long History and Pioneering Spirit, Urology of Virginia Faces a Changing Landscape

July 31st 2016

Michael Fabrizio, MD, and Dana Adams, COO, provide their perspective on the challenges that urology practices face today.

Galeterone Prostate Cancer Trial Closes as PFS Rates Miss Mark

July 26th 2016

The pivotal phase III trial ARMOR 3-SV will be discontinued based on recommendations made by the trial's independent data monitoring committee.

Capmatinib Trial Targets New Molecular Subsets of Patients in NSCLC

July 4th 2016

An ongoing phase II, four-cohort trial involving capmatinib (INC280), an oral MET inhibitor, will determine the clinical activity of the agent in pretreated patients with advanced non-small cell lung cancer who have undergone one or two lines of therapy.

Second-Generation AR-Targeting Agent Explored in High-Risk Prostate Cancer

June 15th 2016

Researchers are hoping the results of a late-stage efficacy and safety study of apalutamide in patients with high-risk, localized, or locally advanced prostate cancer who are receiving primary radiation therapy will demonstrate an improvement in metastasis-free survival.

Atezolizumab Effective in First-Line Setting in Bladder Cancer

June 6th 2016

Patients with metastatic urothelial carcinoma who were ineligible for standard cisplatin-based chemotherapy achieved a 24% reduction in tumor size and had a median survival of 14.8 months after taking the immunotherapy agent atezolizumab (Tecentriq).